


Ukraine

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



Change since previous	ssurvey: ▲ Improvement ▼ Decline	2009		2012		2015		2018
International units	Factor VIII	0.00	A	0.66	•	0.00	A	1.13
per capita	Factor IX	0.00	A	0.11	•	0.00	A	0.22
Organisation	Comprehensive Care Centres (CCC's)	No		No	A	Yes		Yes
of care	Haemophilia Treatment Centres	Yes		Yes		Yes		Yes
	National Haemophilia Council or Co-ordinating Group	No		No		No		No
	Number of groups in decision-making on haemophilia care	0	A	2		2		2
	Number of groups choosing haemophilia treatment products	0	A	1	A	3		3
	National Tender for procurement of factor concentrates			Yes		Yes		Yes
Treatment	Home Treatment			Yes	▼	No	A	Yes
regimens	% of people with haemophilia using home treatment			<10%		<10%		<10%
	Treatment delivered to the patient's home			Some				No
	Prophylaxis treatment availability			Some		Some		Some
	Children currently on prophy (%)			1-25%	A	26-50%		26-50%
	Adults currently on prophy (%)			0		0		1-25%
	Access to ITI (% of people with inhibitors)			1-25%		0		1-25%
Access to	Emergency medicine and acute surgery			Sometimes	A	Yes		Yes
specialist services	Paediatrics			Yes		Yes		Yes
	Infectious disease specialists (especially HIV)			Sometimes	•	Never	A	Sometimes
	Hepatology			Sometimes		Sometimes	•	Never
	Rheumatology			Sometimes				Never
	Orthopaedics			Sometimes	A	Yes		Yes
	Physiotherapy			Sometimes		Sometimes		Sometimes
	Dentistry			Yes		Yes	•	Never
	Obstetrics and Gynaecology			Sometimes				Never
	Genetics			Never		Never		Never
	Social and psychological support			Never	A	Sometimes	•	Never
	Pain management			Sometimes	A	Yes	•	Sometimes
	General surgery			Sometimes	A	Yes		Yes
	Urology			Yes		Yes	•	Sometimes
Share of Expected	Haemophilia A			44%	▼	41%	A	42%
Bleeding Disorder	Haemophilia B			22%	A	24%	A	24%
Prevalence	von Willebrand Disease			1%	A	1%	A	1%
Haemophilia	Pasma-derived factor concentrate	Always	_	Rarely	A	Always		Always
replacement	Recombinant factor concentrate			Rarely	A	Always	•	Sometimes
therapy	Plasma			Rarely	•	Always	A	Sometimes
	Cryoprecipitate			Rarely	•	Always	A	Sometimes
VWD replacement	Plasma-derived factor concentrate			Rarely	A	Always		Always
therapy	DDAVP			Never	A	Always	•	Never
	Plasma			Rarely	•	Always	A	Sometimes
	Cryoprecipitate			Rarely				Never